ES2525451T3 - Uso de óxido nitroso inhalado para prevenir el dolor neuropático inducido por sales de platino - Google Patents

Uso de óxido nitroso inhalado para prevenir el dolor neuropático inducido por sales de platino Download PDF

Info

Publication number
ES2525451T3
ES2525451T3 ES12179606.4T ES12179606T ES2525451T3 ES 2525451 T3 ES2525451 T3 ES 2525451T3 ES 12179606 T ES12179606 T ES 12179606T ES 2525451 T3 ES2525451 T3 ES 2525451T3
Authority
ES
Spain
Prior art keywords
neuropathic pain
nitrous oxide
pain induced
platinum salts
prevent neuropathic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12179606.4T
Other languages
English (en)
Inventor
Baptiste Bessière
Jan Pype
Guy Simonnet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Original Assignee
LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude filed Critical LAir Liquide SA pour lEtude et lExploitation des Procedes Georges Claude
Application granted granted Critical
Publication of ES2525451T3 publication Critical patent/ES2525451T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Medicamento inhalable gaseoso que contiene N2O como principio activo para su utilización por inhalación para prevenir y/o para tratar al menos un dolor neuropático inducido por al menos una sustancia de quimioterapia anticancerígena administrada a un paciente afectado por un cáncer, eligiéndose dicha sustancia de quimioterapia anticancerígena entre las sales de platino.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES12179606.4T 2011-10-14 2012-08-08 Uso de óxido nitroso inhalado para prevenir el dolor neuropático inducido por sales de platino Active ES2525451T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1159296 2011-10-14
FR1159296A FR2981276B1 (fr) 2011-10-14 2011-10-14 Utilisation de protoxyde d'azote ou de xenon inhale pour prevenir des douleurs neuropathiques induites par une chimiotherapie anticancereuse

Publications (1)

Publication Number Publication Date
ES2525451T3 true ES2525451T3 (es) 2014-12-23

Family

ID=46601718

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12179606.4T Active ES2525451T3 (es) 2011-10-14 2012-08-08 Uso de óxido nitroso inhalado para prevenir el dolor neuropático inducido por sales de platino

Country Status (10)

Country Link
US (1) US20130095194A1 (es)
EP (2) EP2581091B1 (es)
JP (1) JP2013121943A (es)
CN (1) CN103040859B (es)
CA (1) CA2785504A1 (es)
DK (1) DK2581091T3 (es)
ES (1) ES2525451T3 (es)
FR (1) FR2981276B1 (es)
PL (1) PL2581091T3 (es)
PT (1) PT2581091E (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3004355B1 (fr) * 2013-04-15 2015-04-03 Air Liquide Utilisation de xenon pour limiter la migration de cellules tumorales
FR3021220B1 (fr) * 2014-05-21 2017-08-25 Air Liquide Association de xenon et d’un antioxydant pour lutter contre une maladie neurodegenerative de type maladie de parkinson
FR3095589B1 (fr) 2019-05-02 2021-05-07 Air Liquide Mélange gazeux inhalable pour traiter les douleurs chroniques chez des patients recevant des médicaments de plusieurs classes thérapeutiques
EP3868361A1 (fr) 2020-02-20 2021-08-25 L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Mélange gazeux inhalable pour traiter les douleurs chroniques chez des patients sous opioïdes
US20220362286A1 (en) * 2021-05-13 2022-11-17 Penland Foundation Treatment of ards and other conditions caused by acutely elevated cytokine levels and post ards chronic cytokine production using inhaled anesthetics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100203156A1 (en) * 2009-02-09 2010-08-12 Meiler Steffen E Xenon as a treatment for hemoglobinopathy
FR2944969B1 (fr) * 2009-04-29 2011-08-26 Air Liquide Utilisation de n2o gazeux dans le traitement des douleurs chroniques
GB2478356A (en) * 2010-03-05 2011-09-07 Esaturnus Nv Nitrous oxide gas for use in preventing adhesion

Also Published As

Publication number Publication date
CN103040859A (zh) 2013-04-17
FR2981276B1 (fr) 2014-02-28
US20130095194A1 (en) 2013-04-18
PL2581091T3 (pl) 2015-03-31
EP2626075B1 (fr) 2015-03-04
DK2581091T3 (en) 2014-12-15
CA2785504A1 (fr) 2013-04-14
EP2581091B1 (fr) 2014-10-01
EP2626075A1 (fr) 2013-08-14
FR2981276A1 (fr) 2013-04-19
PT2581091E (pt) 2014-11-27
JP2013121943A (ja) 2013-06-20
CN103040859B (zh) 2018-01-12
EP2581091A1 (fr) 2013-04-17

Similar Documents

Publication Publication Date Title
ES2525451T3 (es) Uso de óxido nitroso inhalado para prevenir el dolor neuropático inducido por sales de platino
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
DOP2016000250A (es) Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
BR112015013095A8 (pt) Cânula nasal para distribuição de gás terapêutico a um paciente
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
NI201500163A (es) Composiciones, métodos y sistemas para el suministro por vía respiratoria de tres o más agentes activos.
BR112015008365A2 (pt) composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
CL2015002736A1 (es) Composición farmacéutica de clorhidrato de s-ketamina.
CL2015002534A1 (es) Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112015029353A2 (pt) derivados de pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
IN2014KN02583A (es)
AR070026A1 (es) Conjunto de elementos para la dosificacion de 1-amino-alquilciclohexanos, tal como neramexano, y tratamiento de diversas enfermedades incluyendo el tinnitus
CL2013003497A1 (es) Producto farmacéutico de combinación en forma de polvo seco para administración por medio de un inhalador que comprende una sal de umeclidinio de un grupo definido y 100 mcg/dosis de furoato de fluticasona, sin otros activos adicionales; uso para el tratamiento de enfermedades inflamatorias o del aparato respiratorio.
CY1124713T1 (el) Μεθοδοι χορηγησης υψηλων συγκεντρωσεων νιτρικου οξειδιου
CL2013002700A1 (es) Cápsula suave ingerible que contiene inositol y excipientes, o inositol, excipientes y al menos un principio activo adicional, tal como ácido fólico, polifenoles de cocoa, genisteína, l-arginina, vitamina e, selenio, n-acetilcisteína y melatonina; útil para el tratamiento del ovario poliquístico, resistencia a la insulina y otros
EA201391689A1 (ru) Система доставки лекарственного средства
BR112018001035A2 (pt) compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
ECSP14013155A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
ECSP13012524A (es) Teobromina en combinación con un expectorante o un mucolítico para su uso en terapia
BR112013024791A2 (pt) aclidínio para uso na melhoria da qualidade do sono em pacientes com sintomas respiratórios, composição farmacêutica compreendendo o mesmo e seus usos.
AR088204A1 (es) Medicamentos para el tratamiento de la rinitis alergica que comprenden un antagonista de pgd2 y un antagonista de histamina